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and Pancreatic ß-Cell Function in Korean Patients with New-
Onset Type 2 Diabetes
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Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonnam National University Medical School, 
Gwangju, Korea
Background/Aims: We investigated the associations among body mass index (BMI), insulin resistance, and β-cell func-
tion in Korean patients newly presenting with type 2 diabetes. 
Methods: In total, 132 patients with new-onset type 2 diabetes mellitus were investigated. A standard 75-g oral glucose 
tolerance test was performed, and the indices of insulin secretion and insulin resistance were calculated. 
Results: A higher BMI was associated with higher homeostasis model assessment values for insulin resistance (HOMA-
IR), homeostasis model assessment of β-cell function (HOMA-β), and insulinogenic index as well as lower levels of insulin 
sensitivity index composite (ISIcomp) and disposition index (DI). In multiple regression models, BMI had independent positive 
associations with HOMA-IR, ISIcomp, and HOMA-β and inverse associations with the DI. 
Conclusions: Our results showed that BMI had independent positive associations with indices of insulin resistance and 
an inverse association with β-cell function adjusted for insulin resistance in Korean patients newly presenting with type 2 
diabetes.
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INTRODUCTION
Type 2 diabetes, a heterogeneous disorder characterized 
by impaired insulin secretion and insulin resistance [1], is 
closely related to obesity. Insulin resistance is a constant 
finding in patients with type 2 diabetes, and insulin 
resistance is present years before the onset of the disease 
[2]. Thus, when pancreatic β-cells fail to compensate for 
insulin resistance, hyperglycemia develops. However, an 
ethnic difference underlying the pathogenesis of type 2 
diabetes mellitus appears to exist. Patients with type 2 
diabetes in Korea are characteristically nonobese [3], and 
Korean patients may show different clinical characteristics 
compared to Western patients with type 2 diabetes. 
Mounting evidence indicates that insulin secretory defects 
may be predominant properties in Korean patients with 
type 2 diabetes [4,5]. Although several factors that lead to 
β-cell dysfunction have been suggested, the relationship 
between body mass index (BMI) and insulin secretion 
may be complicated by the impact of the associated insulin 
resistance on β-cell function. Several studies have reported 
that BMI was positively associated with endogenous 
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insulin secretion as assessed by serum C-peptide response 
in type 2 diabetes [6,7]. In addition, BMI has been 
suggested to be positively associated with the decreased 
insulin sensitivity in type 2 diabetes mellitus [8]. Thus, 
because BMI is directly related to insulin resistance and 
type 2 diabetes mellitus, the association between BMI 
and insulin secretion may be a concern in Korean patients 
with type 2 diabetes [8]. However, few analyses have 
been conducted to assess the changes in insulin secretion 
depending on BMI in Koreans. In the present study, 
we investigated the associations among BMI, insulin 
resistance, and β-cell function in Korean patients with 
new-onset type 2 diabetes. 
METHODS
This study, conducted from February 2009 to January 
2011, was approved by the local ethics committee, and 
all participants gave informed consent. In total, 132 
patients with new-onset type 2 diabetes mellitus were 
investigated. Diabetes was diagnosed based on the criteria 
of the American Diabetes Association [9]. To avoid severe 
β-cell dysfunction and to exclude any change in insulin 
secretion or resistance due to medication, subjects were 
confined to having a < 3-month history of hyperglycemia 
and no history of taking medication that affected glucose 
metabolism. Subjects with a family history of diabetes 
in first-degree relatives or with positive glutamic acid 
decarboxylase (GAD) antibodies were also excluded. 
BMI was calculated as weight (kg) divided by the square 
of height (m
2). A standard 75-g oral glucose tolerance 
test (OGTT) was performed after a 10-hour overnight 
fast. Plasma samples were obtained at -10, -5, 0, 30, 60, 
90, and 120 minutes to measure glucose (Hitachi 7600-
110, Hitachi Co., Tokyo, Japan) and insulin (IRMA kit, 
Dainabot, Tokyo, Japan) concentrations. The indices of 
insulin secretion and insulin resistance were calculated as 
follows [10-13]:
Insulinogenic index (IGI) = (I30 - I0) / (G30 - G0) 
  Homeostasis model assessment of β-cell function 
(HOMA-β) = 20 × I0 / (G0 - 3.5) 
  Homeostasis model assessment of insulin resistance 
(HOMA-IR) = I0 × G0 / 22.5 
  Insulin sensitivity index composite (ISIcomp) = 10,000 / 
(G0·I0·Gm·Im)
1/2
Disposition index (DI) = IGI / HOMA-IR
where I0 is fasting plasma insulin, G0 is fasting plasma 
glucose, I30 is insulin 30 minutes after glucose load, G30 
is plasma glucose 30 minutes after glucose load, Gm is the 
mean glucose during the OGTT, and Im is the mean insulin 
during the OGTT.
Glycated hemoglobin (HbA1C) (HLC-723-GHbV, Tosoh, 
Tokyo, Japan), total cholesterol, high-density lipoprotein 
cholesterol, triglycerides (AU5400, Olympus, Tokyo, 
Japan), and free fatty acids (NEFA-HR kit, Wako, Osaka, 
Japan) were also measured.
Statistical analysis
Statistical analysis was performed using SPSS version 
17.0 (SPSS Inc., Chicago, IL, USA). Data are expressed 
as the mean ± SD unless otherwise stated. Variables 
not normally distributed were log-transformed before 
analysis. Linear trends were tested for BMI in the 
regression models. Using the logistic regression model, 
multivariate analyses were performed to analyze the 
associations among BMI, insulin resistance, and β-cell 
function. A p value of < 0.05 was considered statistically 
significant.
RESULTS
   
Table 1 shows the characteristics of the patients with 
type 2 diabetes in this study. The mean age of the subjects 
was 54.8 ± 9.7 years, and the mean BMI was 25.0 ± 1.1 
kg/m
2. The mean concentration of fasting plasma glucose 
was 7.26 ± 1.32 mmol/L, and the median value of fasting 
plasma insulin was 43.0 pmol/L. The median values of 
HOMA-IR and ISIcomp were 1.85 and 4.85, respectively. The 
respective median values of HOMA-β, IGI, and DI were 
34.17, 2.70, and 1.41. Table 2 shows the characteristics 
of the patients with type 2 diabetes according to the 
tertiles of BMI. As BMI increased, the patients had higher 
concentrations of triglycerides, fasting plasma insulin, 
and plasma insulin 2 hours after the glucose load. In 
addition, the patients exhibited higher values of HOMA-
IR and lower levels of ISIcomp as well as higher levels of 
HOMA-β and IGI. However, the DI values decreased as 
BMI increased.68    The Korean journal of Internal Medicine Vol. 27, No. 1, March 2012
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When multiple regression modeling was performed to 
determine the associations among BMI, insulin resistance, 
and β-cell function, BMI was a positive correlate of log-
transformed HOMA-IR and a negative correlate of log-
transformed ISIcomp (Table 3). In addition, BMI was 
positively associated with log-transformed HOMA-β. 
However, BMI was a negative correlate of log-transformed 
DI.
DISCUSSION
We found that in addition to a higher degree of insulin 
resistance, a higher BMI was associated with higher values 
of HOMA-β and IGI in patients with type 2 diabetes. 
However, the higher BMI was associated with a lower DI. 
Thus, our results demonstrated that BMI had independent 
inverse associations with β-cell function adjusted 
for insulin resistance as well as independent positive 
associations with indices of insulin resistance in Korean 
patients newly presenting with type 2 diabetes. 
Various methods have been proposed for estimating 
insulin sensitivity and insulin secretion in vivo. The 
hyperinsulinemic euglycemic clamp is a standard tool for 
estimating insulin sensitivity, but the procedure is complex 
in clinical practice [14,15]. The insulin sensitivity index, 
an ISIcomp, obtained from the OGTT is a good surrogate 
measure of whole-body insulin sensitivity compared to 
the euglycemic clamp study [11]. The insulinogenic index, 
calculated as the ratio of the increment of plasma insulin 
to plasma glucose concentration 30 minutes after the 
OGTT, provides a parameter of early insulin response 
during the test [12]. The indices from OGTT data yield 
measures of dynamic insulin secretion and insulin 
sensitivity, whereas HOMA offers steady-state measures of 
insulin secretion and insulin sensitivity in the basal states. 
HOMA-IR is a tool to estimate insulin sensitivity, which 
is closely correlated with the insulin resistance index as 
assessed by the euglycemic clamp [10]. HOMA-β provides 
good β-cell function estimation to prevailing glucose levels 
compared to the frequent sampling in the intravenous 
glucose tolerance test or the hyperglycemic clamp [10,16]. 
With changes to modern lifestyles in recent years, the 
prevalence of type 2 diabetes has increased in Korea. An 
increasing BMI is known to be a contributing factor for 
the development of type 2 diabetes mellitus in Korea as 
well as in other countries [17,18]. Sung et al. [19] reported 
that obesity is a risk factor for type 2 diabetes mellitus, 
and that the relative risks for diabetes mellitus in subjects 
with a BMI of > 27 kg/m
2 were significantly higher than 
those with a BMI of < 23 kg/m
2. Campbell and Carlson [20] 
demonstrated that BMI was negatively correlated with 
glucose disposal and positively associated with glucose 
production in type 2 diabetes mellitus. Chang et al. [8] also 
reported that BMI was the most important determinant 
of insulin resistance, even in nonobese patients with type 
2 diabetes mellitus. In the present study, a higher BMI 
was associated with decreased insulin sensitivity, which 
supports the positive relationship between BMI and 
insulin resistance in type 2 diabetes mellitus [8]. 
As insulin resistance increases, β-cells compensate by 
Table 1. Clinical and metabolic characteristics of the 
subjects 
Variables Values
Total 132
Age, yr 54.8 ± 9.7
Male, n (%)    70 (53.0)
BMI, kg/m
2 25.0 ± 1.1
Systolic BP, mmHg 132.5 ± 18.1
Diastolic BP, mmHg 79.7 ± 11.7
Total cholesterol, mmol/L 5.35 ± 1.12
Triglyceride, mmol/L 1.70 (1.33)
HDL-cholesterol, mmol/L 1.27 ± 0.30
Free fatty acid, nmol/L 720.0 (441.0)
HbA1C, % 7.2 ± 0.9
Fasting glucose, mmol/L 7.26 ± 1.32
Fasting insulin, pmol/L 43.0 (48.6)
2-hr glucose, mmol/L 14.14 ± 3.28
2-hr insulin, pmol/L 234.0 (256.2)
HOMA-IR 1.85 (2.66)
ISIcomp 4.85 (4.96)
HOMA-β 34.17 (46.51)
IGI 2.70 (3.05)
DI 1.41 (1.91)
Values are presented as mean ± SD or median (interquartile 
range).
BMI, body mass index; BP, blood pressure; HDL, high-density 
lipoprotein; HbA1c, hemoglobin glycation; HOMA-IR, homeostasis 
model assessment of insulin resistance; ISIcomp, insulin sensitivity 
index composite; HOMA-β, homeostasis model assessment of 
β-cell function; IGI, insulinogenic index; DI, disposition index.Chung jO, et al. Body mass index and β-cell function    69
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increasing insulin secretion, resulting in compensatory 
hyperinsulinemia and the maintenance of normal glucose 
tolerance [1]. In an autopsy-based study of individuals 
with normal glucose tolerance, a greater β-cell volume was 
found in obese individuals [21]. Yoon et al. [22] reported 
that type 2 diabetes was associated with reduced β-cell 
mass compared to BMI-matched normal subjects, but 
BMI was also positively correlated with relative β-cell 
volume in Korean patients with type 2 diabetes. These 
results suggest that increased BMI may be related to 
Table 2. Clinical and metabolic characteristics of the patients with type 2 diabetes according to body mass index
BMI, kg/m
2 Tertile 1
(BMI ≤ 23.7)
Tertile 2
(23.7 < BMI ≤ 25.7)
Tertile 3
(25.7 < BMI)
p for trend
No. 43 45 44
Age, yr 56.9 ± 9.7 54.2 ± 9.4 53.5 ± 10.1 0.312
Male, n (%)     23 (53.4)   23 (51.1) 24 (54.5) 0.920
BMI, kg/m
2 22.0 ± 1.0 24.7 ± 0.6 28.3 ± 2.1 < 0.001
Systolic BP, mmHg 132.7 ± 22.6 131.0 ± 14.7 132.7 ± 17.5 0.901
Diastolic BP, mmHg 77.1 ± 13.9 81.0 ± 10.4 80.0 ± 11.2 0.232
Total cholesterol, mmol/L 5.06 ± 1.02 5.66 ± 1.20 5.24 ± 1.12 0.534
Triglyceride, mmol/L (%)  1.30 (0.98) 1.41 (1.18) 2.30 (1.28) 0.026
HDL-cholesterol, mmol/L 1.31 ± 0.34 1.31 ± 0.28 1.17 ± 0.30 0.086
Free fatty acid, nmol/L (%)  631.5 (596.2) 709.5 (512.5) 767.0 (729.0) 0.127
HbA1C, % 7.1 ± 0.9 7.1 ± 0.8 7.3 ± 1.2 0.606
Fasting glucose, mmol/L 7.16 ± 1.35 7.19 ± 1.18 7.50 ± 1.22 0.108
Fasting insulin, pmol/L 29.8 (27.0) 42.3 (48.6) 63.1 (76.0) < 0.001
2-hr glucose, mmol/L 14.61 ± 3.28 13.75 ± 2.91 14.52 ± 3.38 0.909
2-hr insulin, pmol/L 214.6 (141.6) 215.9 (186.8) 348.6 (391.0) 0.024
HOMA-IR    1.38 (1.32) 1.90 (2.71) 3.06 (3.03) < 0.001
ISIcomp  6.23 (5.12)   4.51 (5.00) 3.02 (3.31) < 0.001
HOMA-β  23.87 (28.40) 34.17 (40.12)   43.3 (74.98) 0.002
IGI  2.10 (2.45) 2.60 (2.10) 3.40 (4.07) 0.036
DI  1.94 (2.44) 1.43 (1.97) 1.11 (1.54) 0.022
Values are presented as mean ± SD or median (interquartile range).
BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HbA1c, hemoglobin glycation; HOMA-IR, homeostasis model 
assessment of insulin resistance; ISIcomp, insulin sensitivity index composite; HOMA-β, homeostasis model assessment of β-cell function; 
IGI, insulinogenic index; DI, disposition index.
Table 3. Associations among body mass index, insulin resistance, and β-cell function in subjects with type 2 
diabetes as assessed using multivariate linear regression models
Standard regression coefficient R
2 (adjusted R
2) F value p value
HOMA-IR BMI 0.574 0.329 (0.275) 6.116 < 0.001
ISIcomp BMI -0.539 0.320 (0.265) 5.875 < 0.001
HOMA-β BMI 0.378 0.191 (0.126) 2.954 0.001
IGI BMI 0.212 0.213 (0.150) 3.383 0.060
DI BMI -0.314 0.260 (0.200) 4.285 0.005
Log-transformed variables were used for analysis.
All values were adjusted for age, gender, systolic blood pressure, HbA1C, triglycerides, and free fatty acids.
HOMA-IR, homeostasis model assessment of insulin resistance; BMI, body mass index; ISIcomp, insulin sensitivity index composite; 
HOMA-β, homeostasis model assessment of β-cell function; IGI, insulinogenic index; DI, disposition index.70    The Korean journal of Internal Medicine Vol. 27, No. 1, March 2012
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increased β-cell mass, but the impact of BMI on β-cell 
function is not fully understood in patients with type 
2 diabetes. Several previous studies have suggested 
that the contribution of insulin resistance and insulin 
secretory dysfunction might differ in nonobese and 
obese subjects. Pontiroli et al. [23] reported that patients 
with type 2 diabetes who had a relatively normal body 
weight had lower plasma insulin or C-peptide levels in 
the postprandial state or after a glucagon stimulatory 
test compared to obese subjects with diabetes. Arner 
et al. [24] reported that nonobese Swedes with type 2 
diabetes had impairment in insulin secretion rather than 
decreased insulin sensitivity, whereas obese patients with 
diabetes had both impaired insulin action and secretion. 
Park et al. [3] reported that nonobese Korean patients 
with type 2 diabetes had lower levels of fasting serum 
C-peptide compared to obese subjects. Chang et al. [8] 
also reported that insulin-sensitive patients with diabetes 
were associated with low HOMA-β. In the present study, 
patients with type 2 diabetes who had higher BMI also 
had increased values of HOMA-β and IGI. In addition, 
in the multivariate analysis and for indices of insulin 
resistance, BMI was a positive association for HOMA-β or 
IGI, similar to previous studies [6,7,22,25]. However, as 
reported by Kahn et al. [13], evaluation of β-cell function 
may require adjustment for insulin sensitivity. The DI, the 
composite measure of β-cell function, may reflect the true 
underlying cellular function. In the present study, as BMI 
increased, the DI decreased. In the multivariate analysis, 
BMI had an independent inverse association with the DI. 
Thus, our results showed that when insulin sensitivity was 
also considered, BMI might be inversely associated with 
β-cell function, although BMI had a positive association 
with relative β-cell volume in Korean patients with type 2 
diabetes as reported by Yoon et al. [22]. Thus, our findings 
may suggest that increasing BMI possibly contributes to 
further deterioration of β-cell function with associated 
increasing insulin resistance regardless of the presence of 
obesity in Korean patients with type 2 diabetes. However, 
further investigations are required to evaluate the direct 
relationship between β-cell function and mass with 
increasing BMI in such patients. 
In conclusion, our results show that BMI had positive 
associations with indices of insulin resistance and inverse 
associations with β-cell function adjusted for insulin 
resistance in Korean patients newly presenting with type 2 
diabetes. Thus, in clinical practice, managing body weight 
may be important even in nonobese patients with type 
2 diabetes. Further studies are necessary to investigate 
the direct associations between β-cell function and β-cell 
mass with increasing BMI in nonobese and obese patients 
with type 2 diabetes.
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